实例探究 > Blueprint and the LifeArc Ideas Factory

Blueprint and the LifeArc Ideas Factory

公司规模
1,000+
地区
  • Europe
国家
  • United Kingdom
产品
  • Dotmatics Bioregister
  • Dotmatics Blueprint
  • Dotmatics Browser
  • Dotmatics Chemselector
  • Dotmatics Reaction Workflows
技术栈
  • Python ETLs
  • Microservices
  • API layer
实施规模
  • Enterprise-wide Deployment
影响指标
  • Innovation Output
  • Productivity Improvements
技术
  • 应用基础设施与中间件 - 数据可视化
  • 应用基础设施与中间件 - 数据库管理和存储
  • 平台即服务 (PaaS) - 数据管理平台
适用行业
  • 医疗保健和医院
  • 生命科学
适用功能
  • 产品研发
  • 质量保证
用例
  • 质量预测分析
  • 根因分析与诊断
  • 虚拟原型与产品测试
服务
  • 数据科学服务
  • 软件设计与工程服务
关于客户
LifeArc is a UK-based medical research charity that has been bridging the gap between the lab and the patient for over 25 years. The organization provides scientific know-how, technology transfer expertise, and funding to help turn promising early-stage science into medical breakthroughs that transform lives. LifeArc has a strategy of 'making life science life changing' and partners with academics, industry, charities, and patients to transform the way diseases are identified and treated. The organization is committed to investing up to £1.3 billion (approx. $1.75B) by 2030 to advance lab-based scientific discoveries into the next generation of diagnostics, treatments, and cures. Medicines developed from LifeArc's humanized antibodies are already helping patients with a range of conditions, from cancer and Crohn's disease to multiple sclerosis and rheumatoid arthritis. A further eight potential medicines are in clinical trials. Recently, as part of the UK's Therapeutics Antibody Taskforce, LifeArc helped screen over 600 antibodies to create a Covid-19 'antibody cocktail'.
挑战
LifeArc, a UK medical research charity, is dedicated to transforming early-stage science into medical breakthroughs. The organization has a diverse range of scientific activities, from small molecules to engineered antibodies, which generates a variety of data types. This data is stored in operational databases and needs to be accessible for visualization and analytics. LifeArc also collaborates with a number of external organizations, adding to the complexity of the data sources. The challenge was to create an informatics system that could handle this complexity and streamline workflows, while also facilitating the process of ideation, which had historically been separated from informatics.
解决方案
LifeArc leveraged Dotmatics' suite of tools to develop a comprehensive Design Make and Test platform, termed the 'LifeArc Ideas Factory'. The informatics system was built to provide data via Dotmatics Browser, with Blueprint and Browser being well connected. Microservices were used to generate calculated properties, machine learning or models that could be injected into the Blueprint environment. Dotmatics Bioregister was used for registering all biologics to ensure entity uniqueness and protect intellectual property. The Ideas Factory allowed scientists to use Dotmatics Blueprint in a concerted manner, bringing all data to the modelling suite. The system also allowed for the capture of all ideas, whether they came from a modelling suite, cheminformatics platform, or a virtual reality (VR) environment. In the VR environment, researchers could combine data from Blueprint and molecular models and track the results in an ideas database. Dotmatics Chemselector was also used in VR, allowing chemists to search publicly available databases for analogues or matched-pairs, pull them into VR, do some modelling and use Blueprint for further analysis.
运营影响
  • Streamlined workflows for R&D scientists, allowing them to access all their data for visualization and analytics.
  • Enabled the capture of all ideas, whether they came from a modelling suite, cheminformatics platform, or a virtual reality environment.
  • Provided a comprehensive Design Make and Test platform, termed the 'LifeArc Ideas Factory', leveraging available informatics and modelling tools.
  • Protected intellectual property by registering all biologics using Dotmatics Bioregister.
数量效益
  • Investing up to £1.3 billion (approx. $1.75B) by 2030 to advance lab-based scientific discoveries into the next generation of diagnostics, treatments, and cures.
  • Helped screen over 600 antibodies to create a Covid-19 'antibody cocktail'.
  • Eight potential medicines are in clinical trials.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

相关案例.

联系我们

欢迎与我们交流!
* Required
* Required
* Required
* Invalid email address
提交此表单,即表示您同意 IoT ONE 可以与您联系并分享洞察和营销信息。
不,谢谢,我不想收到来自 IoT ONE 的任何营销电子邮件。
提交

感谢您的信息!
我们会很快与你取得联系。